“AI’s biggest contribution in cardiac monitoring is its speed and efficiency”

vTitan Corporation, a  MedTech company specialises in the design, development, and manufacturing of advanced medical technologies. Operating from an ISO 13485-certified facility, the company holds patents in infusion therapy and radiology, reflecting its focus on breakthrough healthcare solutions.

In an exclusive interview with Rahul Koul, Chief Editor, BioVoice News, Prasad Maganti, CEO, vTitan shared insights on the latest developments in the MedTech sector, his company’s initiatives, challenges, R&D, strategic priorities and more.

India’s medical technology industry is at an inflection point—driven by PLI incentives, rising domestic manufacturing, and increasing adoption of digital and AI-enabled devices. What are the biggest structural gaps that still need to be addressed for India to become a truly global medtech hub, and how can companies like vTitan help bridge them?

India has made strong progress in building manufacturing capacity, but a few structural gaps remain. These include limited access to component-level ecosystems, fragmented regulatory harmonisation with global standards, and the need for deeper clinical validation infrastructure at scale. Another key gap is end-to-end product ownership, many players still depend on imported subsystems or foreign analytics platforms.

Companies like ours help bridge these gaps by developing products entirely in India, from hardware design to AI algorithms and software platforms. This approach not only reduces dependency on imports but also enables faster iteration, better alignment with local clinical needs, and cost efficiencies. As more indigenous players adopt this model, India can transition from being a cost-efficient manufacturing base to a true innovation-led global medtech hub.

How does the company differentiate itself from global and domestic competitors in the infusion therapy, monitoring, and cardiac device spaces?

Medical devices, especially in infusion, monitoring, and cardiac care, require tight integration of hardware reliability, software intelligence, and clinical usability. Our key differentiation lies in owning the entire technology stack, signal acquisition hardware, embedded systems, AI-driven analytics, and device agnostic platforms.

This end-to-end control allows us to optimise performance, pricing, and service simultaneously. Unlike many global players who offer premium-priced products or domestic players who rely on imported components, vTitan delivers clinically robust solutions that are both affordable and customised for Indian and similar healthcare environments. 

vTitan develops its products end-to-end in India. Can you walk us through your approach to R&D and how you balance innovation with affordability?

Our R&D approach starts with identifying real clinical and operational pain points rather than technology-first innovation. We focus on building dependable hardware, followed by software and AI layers that enhance usability, speed, and clinical relevance.

Affordability is achieved by leveraging India’s strong engineering talent, cost-effective R&D ecosystem, and high local component sourcing, up to 85% in many of our products. Innovation and affordability are not trade-offs for us; they reinforce each other when products are designed specifically for scale, ease of use, and local workflows.

How do you measure the clinical impact of your devices in hospitals and home care environments?

Clinical impact is measured through multiple indicators, including accuracy of data capture, reduction in clinician workload, response times to clinical events, and adoption across different care settings. In hospitals, this includes use in ICUs, step-down units, and diagnostic workflows.

In home care environments, the focus shifts to continuity of monitoring, early event detection, and ease of use for patients and caregivers. Feedback from clinicians and service providers, along with outcome-based observations such as reduced readmissions or earlier interventions, plays a critical role in validating impact.

Is global expansion part of your growth strategy? If yes, which markets are you prioritizing and why?

Yes, global expansion is an important part of our long-term strategy. 

We are CDSCO registered in India, ISO 13485:2016 certified, and compliant with key IEC safety standards. Select products have already received US FDA and Indonesia MOH approvals, and CE certification is currently underway.

Our initial focus will be on emerging and mid-income regions where healthcare challenges around access, affordability, and scale are similar to India. These markets are well aligned with our value proposition of cost-effective, clinically validated, and easy-to-deploy medical technologies.

What are the biggest operational challenges you face in scaling medical device manufacturing in India, and how are you addressing them?

Scaling manufacturing involves challenges such as ensuring consistent quality at volume, building reliable local supply chains, and managing regulatory compliance across products and geographies. Component availability and vendor maturity can also be constraints.

We address these by increasing local sourcing, investing in supplier development, and designing products that are modular and scalable. As volumes grow and domestic demand strengthens, many of these challenges naturally ease through economies of scale.

With products like the AI-powered vCardio, how do you see AI reshaping clinical workflows and patient monitoring in resource-constrained settings?

AI’s biggest contribution is speed and efficiency. In cardiac monitoring, AI enables near real-time detection of events and summarises long-duration data into clinically meaningful reports. This significantly reduces the time clinicians spend reviewing raw data.

In resource-constrained settings, this efficiency is critical. AI helps extend specialist oversight to larger populations while still operating within a human-in-the-loop framework, where clinicians review and validate findings before clinical decisions are made.

What are your key strategic priorities for vTitan over the next 3–5 years?

Over the next 5 years, our priorities include deepening our product portfolio across infusion, monitoring, and other critical care segments; expanding our dealer and service networks within India; and entering select global markets.

We will continue investing in AI-driven capabilities, and regulatory certifications. At the same time, maintaining strong growth momentum while staying focused on affordability, quality, and clinical relevance will remain central to our strategy.